SynOx Therapeutics SynOx Therapeutics SynOx Therapeutics

SynOx Therapeutics

Onkologie für seltene Indikationen

SynOx Therapeutics was formed in 2020 through a Series A round of EUR 37 million by HealthCap, Medicxi,  Forbion and Gimv. SynOx will continue the development of emactuzumab after securing world-wide rights for the development, manufacturing and commercialization of emactuzumab under a license agreement with Roche.

Emactuzumab is a potential best-in-class clinical-stage CSF-1R targeted antibody designed to target and deplete macrophages in the tumour tissue. It has shown a favourable safety profile and encouraging efficacy in patients with diffuse tenosynovial giant cell tumours (dTGCT), a rare oncology disease. The disease is characterized by pain, swelling and range of movement limitations resulting in a significant impact on quality of life. It typically affects patients aged 20-50 years with an estimate of 70,000 patients in the US and EU5.
 

Details zur Investition

Land

Ireland

Exit date

Meet our team

Portret Michaël Vlemmix
Michaël
Vlemmix

Partner

Belgien
Portret Bram Vanparys
Bram
Vanparys*

Managing Partner - Head Life Sciences

Belgien
Portret Christoph Kocher
Christoph
Kocher

Principal

Deutschland
Related news Related news Related news